Zimbabwe has turned down a significant US health deal valued at $367m (£272m) over five years due to the United States' request for confidential biological samples.
This move was revealed following a government memo from December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesman has since stated that the US was seeking genetic material for scientific study and commercial gain while was not willing to share the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate process of winding down our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged more talks to reach a deal suitable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Context
Zimbabwe's decision comes after a comparable situation in Kenya, where a high court halted a similar health funding agreement following concerns were raised about the security of Kenyans' health data.
Since returning to office last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
As per statements, 16 nations in Africa have to date signed similar health pacts, constituting over $18.3bn in committed funds.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration could have provided extraordinary advantages for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to surrender its biological resources and data over an extended period, without any equivalent guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"In essence, our country would provide the raw materials for scientific discovery without any certainty that the resulting innovations would be accessible to our population if a future disease outbreak arise."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining systems previously set up through the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme designed to deal with future pandemics.
"This system is intended to guarantee that when a nation contributes its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to create them."
These objections over the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to ongoing dialogue with our American counterparts on how future co-operation could be designed in a manner that respects the independence and interests of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it understood the government's concerns, but recommended that negotiations must proceed given that much of the nation's Aids initiatives depended on international support.
"If technical issues arise, such as those involving information security or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," the group said.
The situation emphasises the ongoing challenges between receiving crucial international aid and safeguarding local interests in an increasingly data-driven world.